More than Mediterranean: Exploring and acknowledging the benefits of diverse cultural and nutritional heritages

Post-hoc analy­ses are gen­er­al­ly a ma­jor no-no for the FDA, but agency re­view­ers sig­naled their open­ness to con­sid­er­ing them in the case of Ipsen’s po­ten­tial

Over the last decade, one tech gi­ant af­ter an­oth­er has tried to get in­to health­care and failed. Ama­zon’s at­tempt to re­shape costs and de­liv­ery sput­tered